Associate Justice Neil Gorsuch (AP Photo/J. Scott Applewhite)
SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen
In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9.
The win for Sanofi and Regeneron is a setback for companies like Amgen who are looking to patent broad categories of antibodies, but cannot produce each of the antibodies that might fall into such a category.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters